Factor VIIa and its potential therapeutic use in bleeding-associated pathologies

Ulla Hedner

doi:10.1160/th08-07-0434

January 1, 2008Thrombosis and Haemostasis

Factor VIIa and its potential therapeutic use in bleeding-associated pathologies

View at Publisher

Ask AI

Bookmark

Share

Why the study?

Does recombinant FVIIa improve haemostasis in patients with haemophilia with inhibitors and other bleeding pathologies?

Structured PICO

Does recombinant FVIIa improve haemostasis in patients with haemophilia with inhibitors and other bleeding pathologies?

P

Population

Patients with haemophilia with inhibitors against FVIII/FIX, as well as patients with other bleeding pathologies such as platelet defects, dilution coagulopathy from trauma/surgery, and postpartum haemorrhage

I

Intervention

Recombinant FVIIa (rFVIIa) (e.g., 90-120 microg/kg every other hour for at least 24 h, or 270 microg/kg single injection)

O

Outcome

Haemostatic efficacy

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Recombinant FVIIa is highly effective for achieving haemostasis in haemophilia patients with inhibitors and shows potential for managing other severe bleeding pathologies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ulla Hedner (2008) studied this question.

synapsesocial.com/papers/6a9413f28e5b8037ce43fb17 https://doi.org/10.1160/th08-07-0434

View at Publisher

Ask AI

Bookmark

Share

Factor VIIa and its potential therapeutic use in bleeding-associated pathologies

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Factor VIIa and its potential therapeutic use in bleeding-associated pathologies

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading